Home Other Building Blocks 2H-1-Benzopyran-2-one, 4,7-dihydroxy-3-(3-oxo-1-phenylbutyl)-

2H-1-Benzopyran-2-one, 4,7-dihydroxy-3-(3-oxo-1-phenylbutyl)-

CAS No.:
17834-03-6
Catalog Number:
AG0025Z0
Molecular Formula:
C19H16O5
Molecular Weight:
324.3273
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
Product Description
Catalog Number:
AG0025Z0
Chemical Name:
2H-1-Benzopyran-2-one, 4,7-dihydroxy-3-(3-oxo-1-phenylbutyl)-
CAS Number:
17834-03-6
Molecular Formula:
C19H16O5
Molecular Weight:
324.3273
MDL Number:
MFCD00272668
IUPAC Name:
4,7-dihydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
InChI:
InChI=1S/C19H16O5/c1-11(20)9-15(12-5-3-2-4-6-12)17-18(22)14-8-7-13(21)10-16(14)24-19(17)23/h2-8,10,15,21-22H,9H2,1H3
InChI Key:
SKFYEJMLNMTTJA-UHFFFAOYSA-N
SMILES:
CC(=O)CC(c1c(=O)oc2c(c1O)ccc(c2)O)c1ccccc1
Properties
Complexity:
532  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
324.1g/mol
Formal Charge:
0
Heavy Atom Count:
24  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
324.332g/mol
Monoisotopic Mass:
324.1g/mol
Rotatable Bond Count:
4  
Topological Polar Surface Area:
83.8A^2
Undefined Atom Stereocenter Count:
1  
Undefined Bond Stereocenter Count:
0
XLogP3:
2.3  
Literature
Title Journal
Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors. Cardiovascular drugs and therapy 20150601
Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine. Journal of pharmaceutical sciences 20150101
Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. European journal of clinical pharmacology 20130301
Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. The Journal of pharmacology and experimental therapeutics 20120101
Simultaneous determination of warfarin and 7-hydroxywarfarin enantiomers by high-performance liquid chromatography with ultraviolet detection. Therapeutic drug monitoring 20110201
Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chemical research in toxicology 20100517
Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. Clinical therapeutics 20100201
Determination of plasma warfarin concentrations in Korean patients and its potential for clinical application. The Korean journal of laboratory medicine 20091201
Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chemical research in toxicology 20090701
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. European journal of cancer (Oxford, England : 1990) 20090701
Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug metabolism and pharmacokinetics 20090101
CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. Drug metabolism and disposition: the biological fate of chemicals 20081201
Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarin. Drug metabolism and disposition: the biological fate of chemicals 20081101
The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers. Journal of clinical pharmacy and therapeutics 20080201
Simultaneous determination of warfarin enantiomers and its metabolite in human plasma by column-switching high-performance liquid chromatography with chiral separation. Therapeutic drug monitoring 20070601
Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorganic & medicinal chemistry 20070315
Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050425
Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British journal of clinical pharmacology 20040501
mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica; the fate of foreign compounds in biological systems 20030301
Properties